Dare Bioscience
DARE | NASDAQ
$0.58
-$0.08 (-11.77%)
At close: Nov 16, 2026, 4:00 PM ET
$0.61
+$0.03 (+4.48%)
After-hours:
Nov 16, 2026, 7:42 PM ET
-11.77%
(1D)No price chart data available for 1D timeframe.
Rating
38.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #573/1021 (Top 56%)
Key Statistics
Market Data
Market Cap $8.75M
1D Range
0.58 0.70
52W Range
0.58 3.27
Valuation (TTM)
PE -0.73
PB -15.62
EV/EBITDA -0.34
Valuation (NTM)
Forward PE 0.17
Forward PEG 0.01
Price Target $1.50
Cash Flow
FCF Yield -134.3%
SBC Adj. FCF Yield -151.5%
SBC Impact -12.8%
Margins
Gross Margin -89.5%
Operating Margin -813.4%
FCF Margin -860.6%
Growth (CAGR)
Revenue 3Y | 5Y -52.8% |
-60.9%
Dil EPS 3Y | 5Y 10.5% |
32.1%
FCF 3Y | 5Y -3.4% |
25.9%
Returns
ROA -49.1%
ROE -748.1%
ROIC -179.1%
Financial Health
Net Cash
$6.87M
Current Ratio 0.99
Interest Coverage -55.72
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XA...
Sector Healthcare
Industry Biotechnology
Employees 23
IPO Date Apr 10, 2014
Website darebioscience.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 16, 2026
EPS
-$0.18
Miss -42.10%
YoY:
+35.71% REV
$47.63K
Miss -97.66%
YoY:
+2005.57%Next Earnings
Apr 1, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$1.50
Upside
+158.62%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove DARE